456 Studies Now Enrolling
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Study Evaluating KTE-C19 in Pediatric Subjects With Acute Lymphoblastic Leukemia or B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
| Sponsor: | KITE Pharma |
| Enrolling: | Male and Female Patients |
| Study Length: | 15 Years |
| Clinic Visits: | 40 |
| IRB Number: | AAAS3695 |
| U.S. Govt. ID: | NCT02625480 |
| Contact: | Dylan Stein: 212-345-9770 / djs2245@cumc.columbia.edu |
Additional Study Information:
The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.
This study is closed
Do You Qualify?
| Does your child have leukemia or B cell Non-Hodgkin Lymphoma? | Yes | No |
| Does your child have measurable disease in the Bone Marrow? | Yes | No |
| Is CD19 tumor expression on blasts after your child's most recent completion of therapy? | Yes | No |
| Does your child have any fungal, bacterial, viral or other infection that is uncontrolled or requiring IV microbials? | Yes | No |
| Is your child taking corticosteroid therapy at a does of or = to 0.7 mg/kg/day? | Yes | No |